ClinicalTrials.gg
CompletedNCT02063386Updated Sep 22, 2015

AZD1722 Open Label, Absorption Distribution Metabolism and Excretion Study

A Phase 1 interventional study of AZD1722 in Healthy Volunteers, sponsored by Ardelyx. Completed at 1 site in United Kingdom. Open to male participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-09-22.

Sponsored by Ardelyx · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Non-randomized
Ages
50 Years and older
Sex
Male
01

Study summary

To assess the absorption, distribution, metabolism and excretion of a single dose of 14C labelled AZD1722 in order to define the rates and routes of elimination of AZD1722 and if formed, metabolites.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Ardelyx is the lead sponsor of 29 studies on the registry; 2 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 4 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male volunteers aged ≥50 years
  • Regular daily bowel movements.
  • Have a (BMI) between 18 and 32 kg/m2 (inclusive) and weigh at least 50 kg and no more than 110 kg.

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder which, in the opinion of the Principal Investigator, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study.
  • History or presence of GI, hepatic or renal disease including GI surgery other than appendectomy or any other condition known to interfere with the ADME of drugs.
  • Loose stools (Bristol Stool Form Score of 6 or 7) ≥2 days in the past 7 days before admission to the study centre
  • Use of medications that are known to affect stool consistency and/or GI motility, including fibre supplements, anti-diarrheals, prokinetic drugs, enemas, probiotic medications or supplements; or salt or electrolyte supplements containing sodium, potassium, chloride, or bicarbonate formulations during the past 7 days before admission to the study centre.
  • Volunteers exposed to radiation levels above background (eg, via X-ray examination) of >5 mSv in the last year, >10 mSv over the last 5 years or a cumulative total of >1 mSv per year of life.
  • Participation in a previously radiolabelled study within the last 5 years
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    AZD1722

    Single oral dose 15 mg of \[14C\]AZD1722

    Drug: AZD1722

Interventions

  • Single oral dose 15 mg of \[14C\]AZD1722

06

What researchers measure

Primary outcomes

  1. Percentage of radioactive dose recovered in urine and feces

    Time frame: Day 1: Pre-dose and up to 168 hours post-dose

  2. Total percentage of radioactive dose recovered from both urine and feces

    Time frame: Day 1: Pre-dose and up to 168 hours post-dose

  3. Concentration of total radioactivity in blood and plasma samples

    Time frame: Timeframe: Day 1: Predose and up to 120 hours

  4. Concentration of AZD1722 in plasma samples

    Time frame: Timeframe: Day 1: Predose and up to 120 hours

Secondary outcomes

  1. Safety variables (adverse events, vital signs, ECGs, clinical laboratory tests)

    Time frame: up to 50 days

07

Study locations

1 site
  • Research Site
    London, United Kingdom
08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2014, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2014
First posted
Feb 14, 2014
Start
Apr 2014
Primary completionActual
May 2014
CompletionActual
May 2014
Last update
Sep 22, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02063386
Lead sponsor
Ardelyx
Responsible party
Sponsor
First posted
Feb 14, 2014
Start date
Apr 2014
Primary completion
May 2014
Completion
May 2014
Last update
Sep 22, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenapanor

Start the discussion